SANOFI-AVENTIS DEUTSCHLAND GMBH

Their core work

Sanofi-Aventis Deutschland is the German R&D arm of Sanofi, one of the world's largest pharmaceutical companies. Within H2020, they contribute deep drug development expertise, clinical trial infrastructure, and proprietary compound libraries to large-scale public-private partnerships focused on diabetes, inflammatory diseases, and drug safety. Their role centers on translational research — bridging laboratory discoveries with clinical application — particularly in biomarker validation, toxicology assessment, and immune-mediated disease characterization. They bring industrial-scale drug data, patient cohorts, and analytical capabilities that academic partners typically cannot access.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Sanofi-Aventis Deutschland focused heavily on diabetes fundamentals — type 1 diabetes biobanking, clinical trial networks, diabetic kidney disease biomarkers — alongside foundational toxicology and drug safety work. From 2018 onward, the focus broadened significantly into inflammatory skin diseases (atopic dermatitis, psoriasis), immune-mediated disease mechanisms, and multi-omics data integration approaches. There is a clear trajectory from single-disease biomarker studies toward cross-disease immune profiling and computational approaches to treatment response prediction.

Sanofi-Aventis DE is moving toward multi-omics immune profiling and treatment response prediction across inflammatory diseases, signaling interest in precision medicine partnerships beyond their traditional diabetes stronghold.

How they like to work

Sanofi-Aventis Deutschland operates exclusively as a consortium participant — across all 18 projects, they never served as coordinator. This is typical for large pharma in IMI-style public-private partnerships, where they contribute proprietary data, compounds, and clinical infrastructure rather than leading project management. With 332 unique partners across 29 countries, they function as a high-connectivity hub, embedded in Europe's largest health research networks and accessible to a wide range of academic and SME partners.

With 332 unique consortium partners spanning 29 countries, Sanofi-Aventis DE is one of the most broadly connected pharma participants in H2020 health research. Their network is pan-European with particularly strong ties to IMI (Innovative Medicines Initiative) consortia involving major universities, hospitals, and other pharmaceutical companies.

What sets them apart

As a major pharma company participating in 18 H2020 projects, Sanofi-Aventis DE brings something most academic partners cannot: access to proprietary clinical datasets, compound libraries (ESCulab), industrial-scale toxicology data (eTRANSAFE), and real-world drug handling expertise. Their consistent presence across both IMI public-private partnerships and standard RIA projects makes them a bridge between the pharmaceutical industry and the academic research ecosystem. For consortium builders, partnering with Sanofi means gaining access to industrial validation infrastructure and a pathway toward translating research findings into actual drug development pipelines.

Highlights from their portfolio

• INNODIA
  Long-running (2015–2023) flagship type 1 diabetes project with continuation into INNODIA HARVEST, indicating deep commitment and a core strategic priority for Sanofi's diabetes pipeline.
• eTRANSAFE
  Major drug safety data integration initiative combining pre-clinical and clinical toxicology data across pharma companies — a rare example of competitive pharma firms sharing proprietary safety data.
• 3TR
  Ambitious cross-disease project (2019–2026) tackling treatment non-response across autoimmune and inflammatory conditions using single-cell and multi-omics approaches, reflecting Sanofi's strategic shift toward precision immunology.